Form 4: Inovio Pharmaceuticals, Inc. (INO), Humeau Laurent, transaction 02/26/2021

Summary

In this Form 4, Laurent Humeau, Chief Scientific Officer of INOVIO PHARMACEUTICALS, INC. [ INO ], reports receiving on 02/26/2021 an option on 104,833 shares of Common Stock with an exercise price of $ 11.1 and 67,633 Restricted Stock Units. The explanation gives the option vesting as 26,208 shares on February 26, 2021, February 26, 2022 and February 26, 2023 and 26,209 shares on February 26, 2024; the option expires 02/26/2031. The units vest in installments of 22,544, 22,544 and 22,545 shares in February 2022, 2023 and 2024, and can be settled in shares, cash or both. /s/ Laurent Humeau signed on 02/26/2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * Humeau Laurent (Last) (First) (Middle) C/O INOVIO PHARMACEUTICALS, INC. 6769 MESA RIDGE RD. (Street) SAN DIEGO CA 92121 (City) (State) (Zip) | Humeau Laurent | (Last) | (First) | (Middle) | C/O INOVIO PHARMACEUTICALS, INC. | 6769 MESA RIDGE RD. | SAN DIEGO | CA | 92121 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Scientific Officer | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | Chief Scientific Officer
3. Date of Earliest Transaction
 (Month/Day/Year) 02/26/2021
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Common Stock Option | $ 11.1 | 02/26/2021 | A | 104,833 | 02/26/2021 (1) | 02/26/2031 | Common Stock | 104,833 | $ 0 | 104,833 | D
Restricted Stock Unit | (2) | 02/26/2021 | A | 67,633 | (2) | (2) | Common Stock | 67,633 | $ 0 | 67,633 | D
Explanation of Responses:
1. The vesting schedule for the 104,833 options is as follows: 26,208 shares vested on February 26, 2021; 26,208 shares will vest on February 26, 2022; 26,208 shares will vest on February 26, 2023; 26,209 shares will vest on February 26, 2024.
2. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 67,633 restricted stock units is as follows: 22,544 shares will vest on February 26, 2022; 22,544 shares will vest on February 26, 2023; 22,545 shares will vest on February 26, 2024. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.
Remarks:
/s/ Laurent Humeau | 02/26/2021
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File

SEC_INO_4_filed2021-02-26_0001055726-21-000012.xml

Size

17,084 bytes

SHA-256

e8a9219c864ce63b370c3f6de6e65a628eb92d9c3e1da7da76968aec79d0c946

Our copy

SEC_INO_4_filed2021-02-26_0001055726-21-000012.xml

Original

www.sec.gov